NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VCEL stock has increased by 17.4% and is now trading at $14.18. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Vericel.

Vericel Corp (NASDAQ:VCEL) issued its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $26.70 million during the quarter, compared to the consensus estimate of $26.23 million. Vericel had a positive return on equity of 5.87% and a negative net margin of 9.39%. Vericel's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.07) earnings per share. View Vericel's earnings history.

Vericel issued an update on its first quarter 2020 IntraDay earnings guidance on Thursday, April, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $26.39-26.39 million, compared to the consensus revenue estimate of $26.61 million.

5 equities research analysts have issued 1-year price objectives for Vericel's stock. Their forecasts range from $21.00 to $32.00. On average, they anticipate Vericel's stock price to reach $24.25 in the next year. This suggests a possible upside of 71.0% from the stock's current price. View analysts' price targets for Vericel.

Press coverage about VCEL stock has been trending negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vericel earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutVericel.

Some companies that are related to Vericel include Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Cortexyme (CRTX), Twist Bioscience (TWST), Regenxbio (RGNX), Sangamo Therapeutics (SGMO), I-Mab (BDTX), Mesoblast (MESO), Beam Therapeutics (BEAM), Translate Bio (TBIO), Coherus Biosciences (CHRS), NanoString Technologies (NSTG) and Passage Bio (PASG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.51%), Waddell & Reed Financial Inc. (7.24%), State Street Corp (3.96%), UBS Group AG (3.28%), Wells Fargo & Company MN (2.15%) and Nuveen Asset Management LLC (1.74%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Emerald Mutual Fund Advisers Trust, First Washington CORP, Fort Washington Investment Advisors Inc. OH, Calamos Advisors LLC, Russell Investments Group Ltd., Parametric Portfolio Associates LLC, and AQR Capital Management LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, and Michael Halpin. View insider buying and selling activity for Vericel.

VCEL stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Waddell & Reed Financial Inc., Granahan Investment Management Inc. MA, Silvercrest Asset Management Group LLC, Soleus Capital Management L.P., Wells Fargo & Company MN, BlackRock Inc., and Millrace Asset Group Inc.. View insider buying and selling activity for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $14.18.

Vericel has a market capitalization of $639.66 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]